AlphAIAlphAI — Financial news for AI agents
investing.comNOV 41 min read$ZBH

Zimmer Biomet earnings beat by $0.02, revenue topped estimates

Zimmer Biomet (ZBH) reported Q3 EPS of $1.90, beating estimates by $0.02, with revenue at $2.06B, exceeding expectations. The company expects FY 2026 EPS of $8.50-$8.60, below the consensus of $8.54. ZBH stock is up 10.86% over 12 months.

Original reporting
investing.com
Published Nov 4, 2026, 11:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZBH
Bullish
high confidence
Mentioned
$ZBH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The earnings beat and guidance suggest the company is maintaining performance, which may attract short‑term buyers.

02

Market read

Earnings beat provides a modest trading opportunity in ZBH and may slightly lift the healthcare sector.

03

What to watch

Potential headwinds from supply‑chain constraints and upcoming regulatory reviews could temper the positive reaction.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction

Background

Zimmer Biomet (ZBH) is a leading orthopedic implant manufacturer. The Q3 results were released after market close on Nov 4 2026.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Zimmer Biomet reported Q3 EPS of $1.90 beating estimates and gave FY 2026 guidance of $8.50‑$8.60, a fresh earnings disclosure.

Expected impact

likely modest upward pressure as investors price in the beat and guidance.

Evidence & confidence

The beat is small ($0.02) and guidance matches consensus, so the move is expected to be limited but positive.

Market effects

Sector

Medical‑device sector may see slight lift from a major player beating estimates.

Regional

U.S. equities may see a small bump in healthcare indexes.

Global

Limited; impact confined to U.S. listed medical‑device stocks.

Counterpoint

What could challenge this read

The beat is marginal and guidance is flat; the stock could face pressure if investors expected a larger upside.

Key entities

  • company
    Zimmer Biomet

    Orthopedic device maker reporting Q3 earnings.

Read at source← All news

StoryZimmer Biomet posts Q3 2026 results and lifts full‑year outlook

Also covered by

5 outlets

Related articles

NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

rttnews.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet beats Q3 estimates, raises guidance

Zimmer Biomet (ZBH) reported Q3 adjusted EPS of $1.90, beating estimates by $0.02, with revenue of $2.06B, up 3.1% YoY. The company raised its 2026 adjusted EPS guidance to $8.50-$8.60. Shares rose 1.5% post-results. Key segments like Hips and Technology & Data showed strong growth, while Knees declined.

investing.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet (NYSE:ZBH) exceeds Q3 2026 expectations

Zimmer Biomet reported Q3 2026 revenue of $2.06B, beating estimates by 1.1% and growing 3.1% YoY. Adjusted EPS was $1.90, a 1% beat. Management raised full-year adjusted EPS guidance to $8.55. Operating margin declined to 14.9%, while free cash flow margin increased to 18.1%. Constant currency revenue grew 3.7% YoY, down from 8.6% last quarter.

finance.yahoo.com1 min
NOV 4
$ZBHHighAI 8/10

Zimmer: Q3 Earnings Snapshot

Zimmer Biomet Holdings Inc. (ZBH) reported Q3 profit of $191.6M, or $1 per share, beating estimates. Adjusted EPS was $1.90, and revenue was $2.06B, also exceeding forecasts. The company expects full-year EPS of $8.50-$8.60. (Zacks)

finance.yahoo.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Sales Rise 3.1%; Raises 2026 Growth Guidance

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% YoY. EPS was $1.00, adjusted EPS was $1.90. The company raised its 2026 guidance, expecting 3.0%–3.5% revenue growth and adjusted EPS of $8.50–$8.60. Strong performance in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises. Extended agreement with THINK Surgical and opened a new training facility.

tradingview.com1 min